{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ACE2", "Corona virus", "Omicron", "Receptor binding domain", "Spike", "Variant of concern"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35228064", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "23"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "21"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "02", "Day": "25"}], "Language": ["eng"], "ELocationID": ["10.1016/j.biopha.2022.112756", "S0753-3322(22)00144-5"], "Journal": {"ISSN": "1950-6007", "JournalIssue": {"Volume": "148", "PubDate": {"Year": "2022", "Month": "Apr"}}, "Title": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie", "ISOAbbreviation": "Biomed Pharmacother"}, "ArticleTitle": "There is nothing exempt from the peril of mutation - The Omicron spike.", "Pagination": {"StartPage": "112756", "MedlinePgn": "112756"}, "Abstract": {"AbstractText": ["The 2019 corona virus disease (COVID-19) has caused a global chaos, where a novel Omicron variant has challenged the healthcare system, followed by which it has been referred to as a variant of concern (VOC) by the World Health Organization (WHO), owing to its alarming transmission and infectivity rate. The large number of mutations in the receptor binding domain (RBD) of the spike protein is responsible for strengthening of the spike-angiotensin-converting enzyme 2 (ACE2) interaction, thereby explaining the elevated threat. This is supplemented by enhanced resistance of the variant towards pre-existing antibodies approved for the COVID-19 therapy. The manuscript brings into light failure of existing therapies to provide the desired effect, however simultaneously discussing the novel possibilities on the verge of establishing suitable treatment portfolio. The authors entail the risks associated with omicron resistance against antibodies and vaccine ineffectiveness on one side, and novel approaches and targets - kinase inhibitors, viral protease inhibitors, phytoconstituents, entry pathways - on the other. The manuscript aims to provide a holistic picture about the Omicron variant, by providing comprehensive discussions related to multiple aspects of the mutated spike variant, which might aid the global researchers and healthcare experts in finding an optimised solution to this pandemic."], "CopyrightInformation": "Copyright \u00a9 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab, India. Electronic address: tapan.behl@chitkara.edu.in."}], "LastName": "Behl", "ForeName": "Tapan", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab, India."}], "LastName": "Kaur", "ForeName": "Ishnoor", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab, India."}], "LastName": "Sehgal", "ForeName": "Aayush", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab, India."}], "LastName": "Singh", "ForeName": "Sukhbir", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Punjab, India."}], "LastName": "Sharma", "ForeName": "Neelam", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia."}], "LastName": "Anwer", "ForeName": "Md Khalid", "Initials": "MK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan, Saudi Arabia."}], "LastName": "Makeen", "ForeName": "Hafiz A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia."}], "LastName": "Albratty", "ForeName": "Mohammed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia; Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia."}], "LastName": "Alhazmi", "ForeName": "Hassan A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman; School of Health Science, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India."}], "LastName": "Bhatia", "ForeName": "Saurabh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania. Electronic address: simonabngau@gmail.com."}], "LastName": "Bungau", "ForeName": "Simona", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Biomed Pharmacother", "NlmUniqueID": "8213295", "ISSNLinking": "0753-3322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "COVID-19 Vaccines"}, {"RegistryNumber": "0", "NameOfSubstance": "Spike Glycoprotein, Coronavirus"}, {"RegistryNumber": "0", "NameOfSubstance": "Viral Protease Inhibitors"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Cathepsins"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "Angiotensin-Converting Enzyme 2"}], "SupplMeshList": ["SARS-CoV-2 variants"], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Angiotensin-Converting Enzyme 2"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["immunology", "physiopathology"], "DescriptorName": "COVID-19"}, {"QualifierName": ["immunology"], "DescriptorName": "COVID-19 Vaccines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cathepsins"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Immunization Schedule"}, {"QualifierName": [], "DescriptorName": "Immunization, Secondary"}, {"QualifierName": ["methods"], "DescriptorName": "Phytotherapy"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["physiology"], "DescriptorName": "Protein Binding"}, {"QualifierName": ["physiology"], "DescriptorName": "Protein Interaction Domains and Motifs"}, {"QualifierName": ["physiology"], "DescriptorName": "Protein Structural Elements"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": ["metabolism"], "DescriptorName": "Spike Glycoprotein, Coronavirus"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Viral Protease Inhibitors"}], "CoiStatement": "There is no conflict of interest in the submission of the manuscript."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ishigami I., Zatsepin N.A., Hikita M., Conrad C.E., Nelson G., Coe J.D., Basu S., Grant T.D., Seaberg M.H., Sierra R.G., Hunter M.S., Fromme P., Fromme R., Yeh S.R., Rousseau D.L. Crystal structure of CO-bound cytochrome c oxidase determined by serial femtosecond X-ray crystallography at room temperature. Proc. Natl. Acad. Sci. U.S.A. 2017;114:8011\u20138016. doi: 10.1073/pnas.1705628114.", "ArticleIdList": ["10.1073/pnas.1705628114", "PMC5544322", "28698372"]}, {"Citation": "Johns Hopkins Coronavirus Resource Center, (n.d). \u3008https://coronavirus.jhu.edu/vaccines/vaccines-faq\u3009 (accessed December 13, 2021)."}, {"Citation": "Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino C., Rod\u00e9s-Guirao L. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 2021;5:947\u2013953. doi: 10.1038/s41562-021-01122-8.", "ArticleIdList": ["10.1038/s41562-021-01122-8", "33972767"]}, {"Citation": "Tregoning J.S., Flight K.E., Higham S.L., Wang Z., Pierce B.F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 2021;21:626\u2013636. doi: 10.1038/s41577-021-00592-120212110.21.", "ArticleIdList": ["10.1038/s41577-021-00592-120212110.21", "PMC8351583", "34373623"]}, {"Citation": "Krause P.R., Fleming T.R., Peto R., Longini I.M., Figueroa J.P., Sterne J., Cravioto A., Rees H., Higgins J., Boutron I., Pan H., Gruber M.F., Arora N., Kazi F., Gaspar R., Swaminathan S., Ryan M.J., Henao-Restrepo A.M. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398:1377\u20131380.", "ArticleIdList": ["PMC8437678", "34534516"]}, {"Citation": "Vashi A.P., Coiado O.C. The future of COVID-19: a vaccine review. J. Infect. Public Health. 2021;14:1461\u20131465. doi: 10.1016/J.JIPH.2021.08.011.", "ArticleIdList": ["10.1016/J.JIPH.2021.08.011", "PMC8363422", "34454862"]}, {"Citation": "Wang L., Zhou T., Zhang Y., Yang E.S., Schramm C.A., Shi W., Pegu A., Oloniniyi O.K., Henry A.R., Darko S., Narpala S.R., Hatcher C., Martinez D.R., Tsybovsky Y., Phung E., Abiona O.M., Antia A., Cale E.M., Chang L.A., Choe M., Corbett K.S., Davis R.L., DiPiazza A.T., Gordon I.J., Hait S.H., Hermanus T., Kgagudi P., Laboune F., Leung K., Liu T., Mason R.D., Nazzari A.F., Novik L., O'Connell S., O'Dell S., Olia A.S., Schmidt S.D., Stephens T., Stringham C.D., Talana C.A., Teng I.T., Wagner D.A., Widge A.T., Zhang B., Roederer M., Ledgerwood J.E., Ruckwardt T.J., Gaudinski M.R., Moore P.L., Doria-Rose N.A., Baric R.S., Graham B.S., McDermott A.B., Douek D.C., Kwong P.D., Mascola J.R., Sullivan N.J., Misasi J. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021;373:373. doi: 10.1126/science.abh1766.", "ArticleIdList": ["10.1126/science.abh1766", "PMC9269068", "34210892"]}, {"Citation": "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, (n.d.). \u3008https://www.who.int/news/item/26\u201311-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern\u3009 (accessed December 9, 2021)."}, {"Citation": "Kannan S.R., Spratt A.N., Sharma K., Chand H.S., Byrareddy S.N., Singh K. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. J. Autoimmun. 2022;126", "ArticleIdList": ["PMC8666303", "34915422"]}, {"Citation": "Science Brief: Omicron (B.1.1.529) Variant | CDC, (n.d.). \u3008https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html\u3009 (accessed December 9, 2021)."}, {"Citation": "Lupala C.S., Ye Y., Chen H., Su X.D., Liu H. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem. Biophys. Res. Commun. 2022;590:34\u201341.", "ArticleIdList": ["PMC8702632", "34968782"]}, {"Citation": "Hoffmann M., Kr\u00fcger N., Schulz S., Cossmann A., Rocha C., Kempf A., Nehlmeier I., Graichen L., Moldenhauer A.S., Winkler M.S., Lier M., Dopfer-Jablonka A., J\u00e4ck H.M., Behrens G., P\u00f6hlmann S. The Omicron variant is highly resistant against antibody-mediated neutralization \u2013 implications for control of the COVID-19 pandemic. Cell. 2022;185:447\u2013456. doi: 10.1016/j.cell.2021.12.032. (doi: https://doi.org/)", "ArticleIdList": ["10.1016/j.cell.2021.12.032", "PMC8702401", "35026151"]}, {"Citation": "Kupferschmidt K. Where did 'weird' Omicron come from? Science. 2021;374:1179. doi: 10.1126/science.acx9738.", "ArticleIdList": ["10.1126/science.acx9738", "34855502"]}, {"Citation": "Haseltine W. Omicron: The Sum Of All Fears 2021. \u3008https://www.forbes.com/sites/williamhaseltine/2021/12/08/omicron-the-sum-of-allfears/?sh=2ef4182d5b51\u3009."}, {"Citation": "Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., COVID- Genomics UK (COG-UK) C., Peacock S.J., Robertson D.L. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409\u2013424. doi: 10.1038/s41579-021-00573-0.", "ArticleIdList": ["10.1038/s41579-021-00573-0", "PMC8167834", "34075212"]}, {"Citation": "Li Q., Nie J., Wu J., Zhang L., Ding R., Wang H., Zhang Y., Li T., Liu S., Zhang M., Zhao C., Liu H., Nie L., Qin H., Wang M., Lu Q., Li X., Liu J., Liang H., Shi Y., Shen Y., Xie L., Zhang L., Qu X., Xu W., Huang W., Wang Y. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2362\u20132371. doi: 10.1016/j.cell.2021.02.042. e2369.", "ArticleIdList": ["10.1016/j.cell.2021.02.042", "PMC7901273", "33735608"]}, {"Citation": "Liu Z., VanBlargan L.A., Bloyet L.M., Rothlauf P.W., Chen R.E., Stumpf S., Zhao H., Errico J.M., Theel E.S., Liebeskind M.J., Alford B., Buchser W.J., Ellebedy A.H., Fremont D.H., Diamond M.S., Whelan S. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29:477\u2013488. doi: 10.1016/j.chom.2021.01.014. e474.", "ArticleIdList": ["10.1016/j.chom.2021.01.014", "PMC7839837", "33535027"]}, {"Citation": "Meng B., Kemp S.A., Papa G., Datir R., Ferreira I., Marelli S., Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A., Mlcochova P., COVID- Genomics UK (COG-UK) C., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M., De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L., Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35 doi: 10.1016/j.celrep.2021.109292.", "ArticleIdList": ["10.1016/j.celrep.2021.109292", "PMC8185188", "34166617"]}, {"Citation": "Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S., Schaefer-Babajew D., Cipolla M., Gaebler C., Lieberman J.A., Oliveira T.Y., Yang Z., Abernathy M.E., Huey-Tubman K.E., Hurley A., Turroja M., West K.A., Gordon K., Millard K.G., Ramos V., Da Silva J., Xu J., Colbert R.A., Patel R., Dizon J., Unson-O'Brien C., Shimeliovich I., Gazumyan A., Caskey M., Bjorkman P.J., Casellas R., Hatziioannou T., Bieniasz P.D., Nussenzweig M.C. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616\u2013622. doi: 10.1038/s41586-021-03324-6.", "ArticleIdList": ["10.1038/s41586-021-03324-6", "PMC8503938", "33567448"]}, {"Citation": "Cerutti G., Guo Y., Liu L., Liu L., Zhang Z., Luo Y., Huang Y., Wang H.H., Ho D.D., Sheng Z., Shapiro L. Cryo-EM structure of the SARS-CoV-2 omicron spike. Cell Rep. 2022", "ArticleIdList": ["PMC8818377", "35172173"]}, {"Citation": "Hoffmann M., Kleine-Weber H., Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78:779\u2013784. doi: 10.1016/j.molcel.2020.04.022. e775.", "ArticleIdList": ["10.1016/j.molcel.2020.04.022", "PMC7194065", "32362314"]}, {"Citation": "Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L., Zeldin D.C., Tabak L.A., Ten Hagen K.G. Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation. Proc. Natl. Acad. Sci. U.S.A. 2021;118:118. doi: 10.1073/pnas.2109905118.", "ArticleIdList": ["10.1073/pnas.2109905118", "PMC8617502", "34732583"]}, {"Citation": "Hoffmann M., Kleine-Weber H., Schroeder S., Kr\u00fcger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., M\u00fcller M.A., Drosten C., P\u00f6hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013280. doi: 10.1016/j.cell.2020.02.052. e278.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Schmidt F., Weisblum Y., Muecksch F., Hoffmann H.H., Michailidis E., Lorenzi J., Mendoza P., Rutkowska M., Bednarski E., Gaebler C., Agudelo M., Cho A., Wang Z., Gazumyan A., Cipolla M., Caskey M., Robbiani D.F., Nussenzweig M.C., Rice C.M., Hatziioannou T., Bieniasz P.D. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesSARS-CoV-2 neutralizing antibody activity. J. Exp. Med. 2020;217 doi: 10.1084/jem.20201181.", "ArticleIdList": ["10.1084/jem.20201181", "PMC7372514", "32692348"]}, {"Citation": "Arora P., Sidarovich A., Kr\u00fcger N., Kempf A., Nehlmeier I., Graichen L., Moldenhauer A.S., Winkler M.S., Schulz S., J\u00e4ck H.M., Stankov M.V., Behrens G., P\u00f6hlmann S., Hoffmann M. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Rep. 2021;37 doi: 10.1016/j.celrep.2021.109825.", "ArticleIdList": ["10.1016/j.celrep.2021.109825", "PMC8487035", "34614392"]}, {"Citation": "Xu H., Wang B., Zhao T.N., Liang Z.T., Peng T.B., Song X.H., Wu J.J., Wang Y.C., Su X.D. Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants. Cell Res. 2021;31:1126\u20131129. doi: 10.1038/s41422-021-00554-1.", "ArticleIdList": ["10.1038/s41422-021-00554-1", "PMC8413711", "34480123"]}, {"Citation": "Cao Y., Wang J., Jian F., et al. B.1.1.529 Escapes the Majority of SARS-CoV-2 Neutralizing Antibodies of Diverse Epitopes. BioRxiv 2021. \u300810.1101/2021.12.07.4703922021.12.07.470392\u3009.", "ArticleIdList": ["10.1101/2021.12.07.4703922021.12.07.470392"]}, {"Citation": "Monteil V., Kwon H., Prado P., Hagelkr\u00fcys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Hurtado Del Pozo C., Prosper F., Romero J.P., Wirnsberger G., Zhang H., Slutsky A.S., Conder R., Montserrat N., Mirazimi A., Penninger J.M. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905\u2013913. doi: 10.1016/j.cell.2020.04.004. e907.", "ArticleIdList": ["10.1016/j.cell.2020.04.004", "PMC7181998", "32333836"]}, {"Citation": "Liu L., Iketani S., Guo Y., Chan J.F., Wang M., Liu L., Luo Y., Chu H., Huang Y., Nair M.S., Yu J., Chik K.K., Yuen T.T., Yoon C., To K.K., Chen H., Yin M.T., Sobieszczyk M.E., Huang Y., Wang H.H., Sheng Z., Yuen K.Y., Ho D.D. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2021 doi: 10.1038/s41586-021-04388-0.", "ArticleIdList": ["10.1038/s41586-021-04388-0", "35016198"]}, {"Citation": "Damas J., Hughes G.M., Keough K.C., Painter C.A., Persky N.S., Corbo M., Hiller M., Koepfli K.P., Pfenning A.R., Zhao H., Genereux D.P., Swofford R., Pollard K.S., Ryder O.A., Nweeia M.T., Lindblad-Toh K., Teeling E.C., Karlsson E.K., Lewin H.A. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. Proc. Natl. Acad. Sci. U.S.A. 2020;117:22311\u201322322. doi: 10.1073/pnas.2010146117.", "ArticleIdList": ["10.1073/pnas.2010146117", "PMC7486773", "32826334"]}, {"Citation": "Lupala C.S., Kumar V., Su X.D., Wu C., Liu H. Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain. Comput. Biol. Med. 2021;141 doi: 10.1016/j.compbiomed.2021.105017.", "ArticleIdList": ["10.1016/j.compbiomed.2021.105017", "PMC8565036", "34758907"]}, {"Citation": "Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P\u00e9rez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck RW Jr, Hammitt L.L., T\u00fcreci \u00d6., Nell H., Schaefer A., \u00dcnal S., Tresnan D.B., Mather S., Dormitzer P.R., \u015eahin U., Jansen K.U., Gruber W.C., Clinical Trial G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl. J. Med. 2020;383:2603\u20132615. doi: 10.1056/NEJMoa2034577.", "ArticleIdList": ["10.1056/NEJMoa2034577", "PMC7745181", "33301246"]}, {"Citation": "Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub H.H., Al Kanaani Z., Al Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul Rahim H.F., Nasrallah G.K., Al Kuwari M.G., Al Romaihi H.E., Butt A.A., Al-Thani M.H., Al Khal A., Bertollini R., Abu-Raddad L.J. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. New Engl. J. Med. 2021;385 doi: 10.1056/NEJMoa2114114.", "ArticleIdList": ["10.1056/NEJMoa2114114", "PMC8522799", "34614327"]}, {"Citation": "Wei C., Shan K.J., Wang W., et al. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J. Genet. Genom. 2021 doi: 10.1016/j.jgg.2021.12.003.", "ArticleIdList": ["10.1016/j.jgg.2021.12.003", "PMC8702434", "34954396"]}, {"Citation": "Khan N.A., Al-Thani H., El-Menyar A. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med. Infect. Dis. 2022;45 doi: 10.1016/j.tmaid.2021.102246.", "ArticleIdList": ["10.1016/j.tmaid.2021.102246", "PMC8687713", "34942376"]}, {"Citation": "C. Kuhlmann, C.K. Mayer, M. Claassen\u00a0et al., Breakthr. Infect. SARS-CoV-2 omicron Var. Boost. dose mRNA Vaccin. December 9, 2021 doi:\u00a010.2139/ssrn.3981711.(SSRN)\u3008https://ssrn.com/abstract=3981711\u3009."}, {"Citation": "Pfizer. Pfizer and BioNTech Provide Update on Omicron Variant. Press release. Wednesday, December 08, 2021 - 06:54am. \u3008https://www.pfizer.com/news/press-release/press-releasedetail/pfizer-and-biontech-provide-update-omicron-variant\u3009. (Last accessed December 12, 2021."}, {"Citation": "Billy J., Gardner A., Kilpatrick M. Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers. medRxiv 2021;12:21267594, \u300810.1101/2021.12.10.21267594\u3009.", "ArticleIdList": ["10.1101/2021.12.10.21267594"]}, {"Citation": "Fortune. Health COVID-19 Vaccines. Singapore finds two breakthrough Omicron cases in residents who got COVID booster shots. (Last accessed December 12, 2021. \u3008https://fortune.com/2021/12/09/singapore-omicron-variant-covid-cases-breakthrough-vaccine-pfizer-biontech/?queryly=related_article\u3009."}, {"Citation": "Voysey M., Clemens S.A.C., Madhi S.A., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111. doi: 10.1016/S0140-6736(20)32661-1.", "ArticleIdList": ["10.1016/S0140-6736(20)32661-1", "PMC7723445", "33306989"]}, {"Citation": "Barros-Martins J., Hammerschmidt S.I., Cossmann A., et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat. Med. 2021;27:1525\u20131529. doi: 10.1038/s41591-021-01449-9.", "ArticleIdList": ["10.1038/s41591-021-01449-9", "PMC8440184", "34262158"]}, {"Citation": "Behrens G.M., Cossmann A., Stankov M.V., et al. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1- S/BNT162b2 vaccination. Lancet. 2021;398:1041\u20131042. doi: 10.1016/S0140-6736(21)01891-2.", "ArticleIdList": ["10.1016/S0140-6736(21)01891-2", "PMC8372487", "34416198"]}, {"Citation": "Bar-On Y.M., Goldberg Y., Mandel M., et al. Protection against Covid-19 by BNT162b2 Booster across Age Groups. N. Engl. J. Med. 2021 doi: 10.1056/NEJMoa2115926.", "ArticleIdList": ["10.1056/NEJMoa2115926", "PMC8728796", "34879188"]}, {"Citation": "Callaway E. COVID vaccine boosters: the most important questions. Nature. 2021;596:178\u2013180. doi: 10.1038/d41586-021-02158-6.", "ArticleIdList": ["10.1038/d41586-021-02158-6", "34354274"]}, {"Citation": "Krause P.R., Fleming T.R., Peto R., et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398:1377\u20131380. doi: 10.1016/S0140-6736(21)02046-8.", "ArticleIdList": ["10.1016/S0140-6736(21)02046-8", "PMC8437678", "34534516"]}, {"Citation": "N. Andrews, J. Stowe, F. Kirsebom\u00a0et al., Eff. BNT162b2 (Comirnaty, Pfizer-BioNTech) covid-19 Boost. Vaccin. covid-19 Relat. symptoms Engl.: Test. Negat. case-Control Study medRxiv 11 2021 1266341 doi:\u00a010.1101/2021.11.15.21266341."}, {"Citation": "Bar-On Y.M., Goldberg Y., Mandel M., et al. Protection of BNT162b2 vaccine booster against covid-19 in Israel. New Engl. J. Med. 2021;385:1393\u20131400. doi: 10.1056/NEJMoa2114255.", "ArticleIdList": ["10.1056/NEJMoa2114255", "PMC8461568", "34525275"]}, {"Citation": "Barda N., Dagan N., Cohen C., et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093\u20132100. doi: 10.1016/S0140-6736(21)02249-2.", "ArticleIdList": ["10.1016/S0140-6736(21)02249-2", "PMC8555967", "34756184"]}, {"Citation": "Patalon T., Gazit S., Pitzer V.E., et al. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern. Med. 2021 doi: 10.1001/jamainternmed.2021.7382.", "ArticleIdList": ["10.1001/jamainternmed.2021.7382", "PMC8634151", "34846533"]}, {"Citation": "Rosenberg E.S., Holtgrave D.R., Dorabawila V., et al. New COVID-19 cases and hospitalizations among adults, by vaccination status - New York. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1150\u20131155. doi: 10.15585/mmwr.mm7034e1.", "ArticleIdList": ["10.15585/mmwr.mm7034e1", "PMC8389393", "34437517"]}, {"Citation": "Thomas S.J., Moreira E.D., Jr., Kitchin N., et al. C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. New Engl. J. Med. 2021;385:1761\u20131773. doi: 10.1056/NEJMoa2110345.", "ArticleIdList": ["10.1056/NEJMoa2110345", "PMC8461570", "34525277"]}, {"Citation": "Mevorach D., Anis E., Cedar N., et al. Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel. New Engl. J. Med. 2021;385:2140\u20132149. doi: 10.1056/NEJMoa2109730.", "ArticleIdList": ["10.1056/NEJMoa2109730", "PMC8531987", "34614328"]}, {"Citation": "Cines D.B., Bussel J.B. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. New Engl. J. Med. 2021;384:2254\u20132256. doi: 10.1056/NEJMe2106315.", "ArticleIdList": ["10.1056/NEJMe2106315", "PMC8063912", "33861524"]}, {"Citation": "Kazybay B., Ahmad A., Mu C., et al. Omicron N501Y mutation among SARS-CoV-2 lineages: insilico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine. Travel Med. Infect. Dis. 2022;45 doi: 10.1016/j.tmaid.2021.102242.", "ArticleIdList": ["10.1016/j.tmaid.2021.102242", "PMC8677628", "34929375"]}, {"Citation": "Klann K., Bojkova D., Tascher G., et al. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol. Cell. 2020;80:164\u2013174.", "ArticleIdList": ["PMC7418786", "32877642"]}, {"Citation": "Lupberger J., Duong F.H., Fofana I., et al. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology. 2013;58:1225\u20131235.", "ArticleIdList": ["23519785"]}, {"Citation": "Currier M.G., Lee S., Stobart C.C., et al. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression. PLoS Pathog. 2016;12", "ArticleIdList": ["PMC4859522", "27152417"]}, {"Citation": "Tanjak P., Thiantanawat A., Watcharasit P., Satayavivad J. Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors. Int. J. Oncol. 2018;53:177\u2013188.", "ArticleIdList": ["29693152"]}, {"Citation": "Ru J., Li P., Wang J., et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Chemin. 2014;6:13.", "ArticleIdList": ["PMC4001360", "24735618"]}, {"Citation": "Xie Y., Mu C., Kazybay B., et al. Network pharmacology and experimental investigation of Rhizoma polygonati extract targeted kinase with herbzyme activity for potent. Drug Deliv. Drug Deliv. 2021;28:2187\u20132197. doi: 10.1080/10717544.2021.1977422.", "ArticleIdList": ["10.1080/10717544.2021.1977422", "PMC8526013", "34662244"]}, {"Citation": "Mu C., Sheng Y., Wang Q., et al. Potential compound from herbal food of Rhizoma Polygonati for treatment of COVID-19 analyzed by network pharmacology: viral and cancer signaling mechanisms. J. Funct. Foods. 2021;77", "ArticleIdList": ["PMC7427583", "32837538"]}, {"Citation": "Benassi E., Fan H., Sun Q., et al. Herbal food processing generation of particle assembly mimicking enzymatic activity: the case of Rhizoma polygonati and other natural ingredients of traditional Chinese medicine. Nanoscale Adv. 2021;3:2222\u20132235.", "ArticleIdList": ["PMC9417895", "36133773"]}, {"Citation": "Santamaria S. Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2? Int. J. Biol. Sci. 2021;17:2770\u20132771. doi: 10.7150/ijbs.63969.", "ArticleIdList": ["10.7150/ijbs.63969", "PMC8326129", "34345206"]}, {"Citation": "Sun F., Mu C., Kwok H.F., et al. Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. Int J. Biol. Sci. 2021;17:2348\u20132355. doi: 10.7150/ijbs.57810.", "ArticleIdList": ["10.7150/ijbs.57810", "PMC8241724", "34239361"]}, {"Citation": "Wang Z., Yang L. In the age of omicron variant: paxlovid raises new hopes of COVID-19 recovery. Med. Virol. 2021 doi: 10.1002/jmv.27540.", "ArticleIdList": ["10.1002/jmv.27540", "34936106"]}, {"Citation": "Ma C., Sacco M.D., Hurst B., et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678\u2013692.", "ArticleIdList": ["PMC7294525", "32541865"]}, {"Citation": "Qiao J., Li Y.S., Zeng R., et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science. 2021;371:1374\u20131378.", "ArticleIdList": ["PMC8099175", "33602867"]}, {"Citation": "Owen D.R., Allerton C.M.N., Anderson A.S., et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021:4784. doi: 10.1126/science.abl4784.", "ArticleIdList": ["10.1126/science.abl4784", "34726479"]}, {"Citation": "Zhao Y., Fang C., Zhang Q., et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2021 doi: 10.1007/s13238-021-00883-2.", "ArticleIdList": ["10.1007/s13238-021-00883-2", "PMC8533666", "34687004"]}, {"Citation": "Ullrich S., Ekanayake KB, Otting G., Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332. bioRxiv. 2021. 10.1101/2021.11.28.470226.", "ArticleIdList": ["10.1101/2021.11.28.470226", "PMC8856729", "35182772"]}, {"Citation": "Cully M. A tale of two antiviral targets\u2014and the COVID-19 drugs that bind them. Nat. Rev. Drug Discov. 2021 doi: 10.1038/d41573-021-00202-8.", "ArticleIdList": ["10.1038/d41573-021-00202-8", "34857884"]}, {"Citation": "oral. Antivir. Treat. candidate Reduc. risk Hosp. or. death 89% interim Anal. phase 2/3 EPIC-HR study 2021.Accessed November 5\u3008https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\u3009."}, {"Citation": "Altarawneh H.N., Chemaitelly H., Hasan M.R., Ayoub H.H., Qassim S., AlMukdad S., Coyle P., Yassine H.M., Al-Khatib H.A., Benslimane F.M., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A., Al-Romaihi H.E., Al-Thani M.H., Al-Khal A., Bertollini R., Tang P., Abu-Raddad L.J. Protection against the omicron variant from previous SARS-CoV-2 infection. New Engl. J. Med. 2022 doi: 10.1056/NEJMc2200133.", "ArticleIdList": ["10.1056/NEJMc2200133", "PMC8849180", "35139269"]}, {"Citation": "Hakami A.R. Targeting the RBD of omicron variant (B.1.1.529) with medicinal phytocompounds to abrogate the binding of spike glycoprotein with the hACE2 using computational molecular search and simulation approach. Biology. 2022;11(2):258. doi: 10.3390/biology11020258.", "ArticleIdList": ["10.3390/biology11020258", "PMC8869371", "35205124"]}, {"Citation": "Lall N., et al. Extract from ceratonia siliqua exhibits depigmentation properties. Phytother. Res. 2015;29:1729\u20131736.", "ArticleIdList": ["26201055"]}, {"Citation": "Ayers S., Zink D.L., et al. Flavones from Struthiola argentea with anthelmintic activity in vitro. Phytochemistry. 2008;69:541\u2013545.", "ArticleIdList": ["17923139"]}, {"Citation": "Tshikalange T.E., Meyer J.J.M., Hussein A.A. Antimicrobial activity, toxicity and the isolation of a bioactive compound from plants used to treat sexually transmitted diseases. J. Ethnopharmacol. 2005;96:515\u2013519.", "ArticleIdList": ["15619572"]}, {"Citation": "Adelekan A.M., Prozesky E.A., et al. Bioactive diterpenes and other constituents of croton steenkampianus. J. Nat. Prod. 2008;71:1919\u20131922.", "ArticleIdList": ["18855442"]}, {"Citation": "Hoffmann M., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013280. doi: 10.1016/j.cell.2020.02.052. e278.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Saito A., et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 delta P681R mutation. Nature. 2021 doi: 10.1038/s41586-021-04266-9.", "ArticleIdList": ["10.1038/s41586-021-04266-9", "PMC8828475", "34823256"]}, {"Citation": "Meng B., et al. Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts tropism and fusogenicity. Nature. 2022 doi: 10.1038/s41586-022-04474-x.", "ArticleIdList": ["10.1038/s41586-022-04474-x", "PMC8942856", "35104837"]}, {"Citation": "Dhawan M., et al. Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt. Int. J. Surg. 2022;97 doi: 10.1016/j.ijsu.2021.106198.", "ArticleIdList": ["10.1016/j.ijsu.2021.106198", "PMC8702631", "34958967"]}, {"Citation": "Gao S.J., Guo H., Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert. J. Med. Virol. 2021 doi: 10.1002/jmv.27491.", "ArticleIdList": ["10.1002/jmv.27491", "PMC9015397", "34850421"]}, {"Citation": "Karim S.S.A., Karim Q.A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021 doi: 10.1016/S0140-6736(21)02758-6.", "ArticleIdList": ["10.1016/S0140-6736(21)02758-6", "PMC8640673", "34871545"]}, {"Citation": "Andrews N., Stowe J., Kirsebom F., et al. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study. medRxiv. 2021 doi: 10.1101/2021.11.15.21266341.", "ArticleIdList": ["10.1101/2021.11.15.21266341"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "2", "Day": "3"}, {"Year": "2022", "Month": "2", "Day": "21"}, {"Year": "2022", "Month": "2", "Day": "23"}, {"Year": "2022", "Month": "3", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "1", "Hour": "5", "Minute": "51"}, {"Year": "2022", "Month": "2", "Day": "25"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35228064", "PMC8872818", "10.1016/j.biopha.2022.112756", "S0753-3322(22)00144-5"]}}], "PubmedBookArticle": []}